Corporate news announcement processed and transmitted by Hugin AS.
The issuer is solely responsible for the content of this
announcement.
----------------------------------------------------------------------
--------------
Martinsried/Munich (Germany), Princeton, N.J. and Houston, TX,
November 17, 2009 - Agennix AG (Frankfurt Stock Exchange: AGX) today
announced that the Company will hold a conference call on Monday,
November 23, 2009 at 3 PM CET/9 AM ET to discuss financial results
for the third quarter of 2009 and provide a corporate update. The
results will be published on November 23 in advance of the conference
call.
Participants may listen via live webcast, accessible through the
Agennix Web site at www.agennix.com or via telephone. A replay will
be available on the Web site following the live event. The call will
be conducted in English.
The dial-in numbers for the call are as follows:
Participants in Europe: 0049 69 667775756
0044 20 3003 2666
Participants in the U.S.: 1-646-843-4608
Please dial in 10 minutes before the beginning of the call.
About Agennix
Agennix AG is a publicly traded biopharmaceutical company focused on
developing novel anti-cancer therapies. The Company was formed by the
combination of GPC Biotech AG and Agennix Incorporated. The Company's
most advanced program is talactoferrin, an oral targeted therapy that
is in Phase 3 clinical trials in non-small cell lung cancer. Other
clinical development programs include RGB-286638, a multi-targeted
kinase inhibitor in Phase 1 testing; the oral platinum-based compound
satraplatin; and a topical gel form of talactoferrin for wound
healing. Agennix is a transatlantic company with sites in Munich,
Germany; Princeton, New Jersey and Houston, Texas. For additional
information, please visit the Agennix Web site at www.agennix.com.
This press release contains forward-looking statements, which express
the current beliefs and expectations of the management of Agennix AG.
Such statements are based on current expectations and are subject to
risks and uncertainties, many of which are beyond our control, that
could cause future results, performance or achievements to differ
significantly from the results, performance or achievements expressed
or implied by such forward-looking statements. Actual results could
differ materially depending on a number of factors, and we caution
investors not to place undue reliance on the forward-looking
statements contained in this press release. Forward-looking
statements speak only as of the date on which they are made and
Agennix undertakes no obligation to update these forward-looking
statements, even if new information becomes available in the future.
For further information, please contact:
Agennix AG
Investor Relations & Corporate Communications
Phone: +49 (0)89 8565 2693
ir@agennix.com
In the U.S.: Laurie Doyle
Director, Investor Relations & Corporate Communications
Phone: +1 609 524 5884
laurie.doyle@agennix.com
Additional media contacts for Europe:
MC Services AG
Phone: +49 (0) 89 210 228 0
Raimund Gabriel
raimund.gabriel@mc-services.eu
Hilda Juhasz
hilda.juhasz@mc-services.eu
Additional investor contact for Europe:
Trout International LLC
Lauren (Rigg) Williams, Vice President
Phone: +44 207 936 9325
lrigg@troutgroup.com
--- End of Message ---
Agennix AG
Fraunhoferstr. 20 Martinsried Germany
ISIN:
DE000A1A6XX4;
Listed: Regulierter Markt in Frankfurter Wertpapierbörse, Prime
Standard in Frankfurter Wertpapierbörse;
Copyright © Hugin AS 2009. All rights reserved.